SynthesisNeurosurgical review2025
Illuminating glioma surgery: A meta-analysis of Raman spectroscopy for intraoperative decision-making.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precise tumor characterization is key in glioma surgery. Raman spectroscopy offers real-time, molecular-level tissue analysis for intraoperative guidance. This meta-analysis synthesizes current applications of Raman spectroscopy in glioma surgery. Systematic literature search in PubMed/MEDLINE and the Cochrane Library through March 15, 2025, using the algorithm: "Raman AND (brain tumor OR glioma OR glioblastoma) AND (surgery OR intraoperative)" retrieved 206 studies. Studies evaluating intraoperative Raman spectroscopy for glioma diagnosis, using histopathology/molecular biology as the reference standard, were included. Meta-analysis, following PRISMA-DTA/STARD guidelines, compared Raman spectroscopy to histopathology/molecular biology. Pooled analyses assessed Raman spectroscopy's ability to: (1) delineate tumor margins; (2) grade high-grade (HGG) versus low-grade gliomas (LGG); (3) distinguish astrocytomas from oligodendrogliomas; (4) classify IDH-wildtype (IDHwt) versus IDH-mutant (IDHmut) gliomas; and (5) discriminate gliomas from other brain tumors. From 206 studies, 19 were used in pooled analyses. For tumor vs. normal tissue, pooled sensitivity was 95.66%, and specificity was 86.13%, with heterogeneity due to varying definitions of "normal" tissue. Differentiation of HGG vs. LGG had Limited data; one study showed 91% sensitivity and 87% specificity. Astrocytoma vs. oligodendroglioma differentiation showed a pooled sensitivity of 89.9% and specificity of 86.4%. IDHwt vs. IDHmut glioma classification had a pooled sensitivity of 91.4% and specificity of 90.4%. For glioma vs. other brain tumors, pooled sensitivity was 91.2% and specificity was 91.6%. Raman spectroscopy shows potential for intraoperative glioma characterization. Standardization is needed for better comparison across studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.